Background: Biliary obstruction affects the renal response to ischemia and also elicits a hepatic cytokine response. Using a murine model, we now test the hypothesis that these hepatic cytokines help determine the outcome of ischemic acute renal failure. Methods: C3H/HEN mice were subjected to bile duct ligation 24 h (ABDL) or 7 days (CBDL) prior to induction of acute ischemic renal failure (ARF). Serum creatinine (Scr), cytokine mRNA abundance, and renal histology were studied 24 h after renal ischemia. Results: ABDL prior to ARF resulted in amelioration of renal injury (Scr 0.7 ± 0.1 mg/dl compared to 2.5 ± 0.1 mg/dl in sham/ARF group, (mean ± SE, n = 11/group). CBDL exacerbated renal injury. Increased hepatic mRNA for interleukin-10 (IL10) and interleukin-1 receptor antagonist (IL1RA) was detected in the ABDL/ARF group but not in the CBDL/ARF group. These data suggest that hepatic production of IL10 and IL1RA in response to ABDL ameliorates ischemic ARF, an effect that is lost after several days of BDL. Conclusion: Our data support the concept that hepatic cytokines modulate renal injury. This adds a new dimension in our understanding of renal injury in the setting of hepatic disease.

Keywords:
Interleukin-10, Acute renal failure, Interleukin-1 receptor antagonist, Biliary obstruction
1.
Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O’Donnell MP, Rabb H: Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001;108:1283–1290.
2.
Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996;97:1056–1063.
3.
Deng J, Hu X, Hewitt S, Star RA: Alpha melanocyte stimulating hormone (MSH) inhibits renal injury following cisplatin administration, in part, via interleukin 10 (abstract). J Am Soc Nephrol 2001;12:A4184.
4.
Daemen MARC, van de Ven MWCM, Heineman E, Buurman WA: Involvement of endogenous interleukin-10 and tumor necrosis factor-a in renal ischemia-reperfusion injury. Transplantation 1999;67:792–800.
5.
Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH: Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 2001;104:1308–1313.
6.
Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ: Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001;21:5528–5534.
7.
Nesic O, Xu GY, McAdoo D, High KW, Hulsebosch C, Perez-Pol R: IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J Neurotrauma 2001;18:947–956.
8.
Donnahoo KK, Shames BD, Harken AH, Meldrum DR: Review article: The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 1999;162:196–203.
9.
Meldrum KK, Meldrum DR, Hile KL, Yerkes EB, Ayala A, Cain MP, Rink RC, Casale AJ, Kaefer MA: p38 MAPK mediates renal tubular cell TNF-alpha production and TNF-alpha-dependent apoptosis during simulated ischemia. Am J Physiol Cell Physiol 2001;281:C563–C570.
10.
Kielar ML, Rohan JD, Lu CY: The regulation of ischemic acute renal failure by extrarenal organs. Curr Opin Nephrol Hypertens 2002;11:451–457.
11.
Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation (review; 64 refs). N Engl J Med 1999;340:448–454.
12.
Leung N, Croatt AJ, Haggard JJ, Grande JP, Nath KA: Acute cholestatic liver disease protects against glycerol-induced acute renal failure in the rat. Kidney Int 2001;60:1047–1057.
13.
Green J, Better OS: Systemic hypotension and renal failure in obstructive jaundice-mechanistic and therapeutic aspects. J Am Soc Nephrol 1995;5:1853–1871.
14.
Bomzon L, Weinbroum A, Kamenetz L: Systemic hypotension and pressor responsiveness in cholestasis: a study in conscious 3-day bile duct ligated rats. J Hepatol 1990:11:70–76.
15.
Yarger WE: Intrarenal mechanism of salt retention after bile duct ligation in rats. J Clin Invest 1976;57:408–418.
16.
Beierle EA, Vauthey JN, Moldawer LL, Copeland EM: III. Hepatic tumor necrosis factor alpha production and distant organ dysfunction in a murine model of obstructive jaundice. Am J Surg 1996;171:202–206.
17.
Plebani M, Panozzo MP, Basso D, De Paoli M, Biasin R, Infantolino D: Cytokines and the progression of liver damage in experimental bile duct ligation. Clin Exp Pharmacol Physiol 1999;26:358–363.
18.
Baum M, Stirling GA, Dawson JL: Further study into obstructive jaundice and ischaemic renal damage. Br Med J 1969;ii:229–231.
19.
Aoyagi T, Lowenstein LM: The effect of bile acids and renal ischemia on renal function. J Lab Clin Med 1968;71:686–692.
20.
Tajiri K, Miyakawa H, Liu J, Kamiyama T, Marumo F, Sato C: Enhanced renal susceptibility to ischemia-reperfusion injury in the rat with obstructive jaundice. Hepatogastroenterology 1997;44:789–795.
21.
Burne MJ, Haq M, Matsuse H, Mohapatra S, Rabb H: Genetic susceptibility to renal ischemia reperfusion injury revealed in a murine model. Transplantation 2000;69:1023–1025.
22.
Dinarello CA: The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343:732–734.
23.
Frangogiannis NG, Youker KA, Rossen RD, Gwechenberger M, Lindsey MH, Mendoza LH, Michael LH, Ballantyne CM, Smith CW, Entman ML: Cytokines and the microcirculation in ischemia and reperfusion. J Mol Cell Cardiol 1998;30:2567–2576.
24.
Yoshidome H, Kato A, Edwards MJ, Lentsch AB: Interleukin-10 inhibits pulmonary NF-kappaB activation and lung injury induced by hepatic ischemia-reperfusion. Am J Physiol 1999;277:L919–L923.
25.
Huber TS, Gaines GC, Welborn MB, Rosenberg JJ, Seeger JM, Moldawer LL: Anticytokine therapies for acute inflammation and the systemic inflammatory response syndrome: IL-10 and ischemia/reperfusion injury as a new paradigm. Shock 2000;13:425–434.
26.
Frangogiannis NG, Mendoza LH, Lindsey ML, Ballantyne CM, Michael LH, Smith CW, Entman ML: IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 2000;165:2798–2808.
27.
Van Laethem JL, Marchant A, Delvaux A, Goldman M, Robberecht P, Velu T, Deviere J: Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995;108:1917–1922.
28.
Yang Z, Zingarelli B, Szabo C: Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation 2000;101:1019–1026.
29.
Selzman CH, Shames BD, Miller SA, Pulido EJ, Meng X, McIntyre RCJ, Harken AH: Therapeutic implications of interleukin-10 in surgical disease. Shock 1998;10:309–318.
30.
Engles RE, Huber TS, Zander DS, Hess PJ, Welborn MB, Moldawer LL, Seeger JM: Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res 1997;69:425–428.
31.
Spera PA, Ellison JA, Feuerstein GZ, Barone FC: IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998;251:189–192.
32.
Eppinger MJ, Ward PA, Bolling SF, Deeb GM: Regulatory effects of interleukin-10 on lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 1996;112:1301–1305;discussion 1305–1306.
33.
Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA: Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001;60:2118–2128.
34.
Haq M, Norman J, Saba SR, Ramirez G, Rabb H: Role of IL-1 in renal ischemic reperfusion injury. J Am Soc Nephrol 1998:9:614–619.
35.
Clements WD, Erwin P, McCaigue MD, Halliday I, Barclay GR, Rowlands BJ: Conclusive evidence of endotoxaemia in biliary obstruction. Gut 1998;42:293–299.
36.
Van Bossuyt H, Desmaretz C, Gaeta GB, Wisse E: The role of bile acids in the development of endotoxemia during obstructive jaundice in the rat. J Hepatol 1990;10:274–279.
37.
Melnikov VY, Schrier RW, Edelstein CL: Role of interleukin-18 (IL-18) in endotoxemia-induced acute renal failure (ARF) (abstract). J Am Soc Nephrol 2001;12:A4116.
38.
Bailey ME: Endotoxin, bile salts and renal function in obstructive jaundice. Br J Surg 1976;63:774–778.
39.
Daemen MA, Heemskerk VH, van’t Veer C, Denecker G, Wolfs TG, Vandenabeele P, Buurman WA: Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 2000;19;102:1420–1426.
40.
Kimura F, Miyazaki M, Suwa T, Sugiura T, Shinoda T, Itoh H, Ambiru S, Shimizu H, Nakagawa K: Plasma human hepatocyte growth factor concentrations in patients with biliary obstruction. J Gastroenterol Hepatol 2000;15:76–82.
41.
Matsumoto K, Nakamura T: Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59:2023–2038.
42.
Liu Y: Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 2002;11:23–30.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.